Grants and Contributions:
Title:
Development of Technical Capabilities for Product Development
Agreement Number:
901202
Agreement Value:
$180,000.00
Agreement Date:
Apr 2, 2018 - Feb 28, 2021
Description:
The aim of the project is to develop and commercialize pharmaceutical drugs for the treatment of cancer. The Company's current focus is on the generic oncology generic injectible market in the European Union and North America. Currently, Waverley Pharma Inc. has two products WAV-101 and WAV-102 for the treatment of cancer.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Winnipeg, Manitoba, CA R3T 6C6
Reference Number:
172-2018-2019-Q1-901202
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
737463927
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 30 days.
Amendment Date
Dec 16, 2020
Recipient's Legal Name:
Waverley Pharma Inc
Federal Riding Name:
Winnipeg South Centre
Federal Riding Number:
46014
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
3254
Amendments: